Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model

C. F. Pollera, D. Giannarelli

Research output: Contribution to journalArticle

Abstract

Data obtained from 209 patients who entered different prospective randomized antiemetic trials were analyzed to establish the prognostic value of some variables on the control of cisplatin-induced emesis. The antiemetic regimens evaluated included the following: metoclopramide (M) at 1, 2, and 4 mg/kg total dose and a combination of M (4 mg/kg) with dexamethasone (D) (40 mg). Vomiting lasting more than 1 hour (no protection [MP]) was the endpoint selected for the analysis. A logistic model carried out, first on the 110 subjects receiving the M+D regimen and then on the whole sample, selected sex (P = 0.0001), Eastern Cooperative Oncology Group performance status (PS) (P = 0.006), and age (P = 0.01) among the six factors considered. Since the prognostic value of these variables is mostly related to their interaction, three major risk classes were identified. The corresponding NP rates were 26.3%, 42.4%, and 70.8% for the low-risk, intermediate-risk, and high-risk groups, respectively (P = 0.000002). Except for the lowest M level, the observed NP rates were significantly associated to the risk classes, whereas the antiemetic regimen influenced the antiemetic outcome only in the low-risk class. Regardless of the regimen employed, certain patient characteristics, such as sex, PS, and age, significantly affect cisplatin-related emesis and should be carefully considered in planning further studies.

Original languageEnglish
Pages (from-to)1117-1122
Number of pages6
JournalCancer
Volume64
Issue number5
Publication statusPublished - 1989

Fingerprint

Cisplatin
Vomiting
Antiemetics
Logistic Models
Metoclopramide
Dexamethasone

ASJC Scopus subject areas

  • Cancer Research

Cite this

Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. / Pollera, C. F.; Giannarelli, D.

In: Cancer, Vol. 64, No. 5, 1989, p. 1117-1122.

Research output: Contribution to journalArticle

@article{60bea1eca98b4844ba52a0a5ba6c6f37,
title = "Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model",
abstract = "Data obtained from 209 patients who entered different prospective randomized antiemetic trials were analyzed to establish the prognostic value of some variables on the control of cisplatin-induced emesis. The antiemetic regimens evaluated included the following: metoclopramide (M) at 1, 2, and 4 mg/kg total dose and a combination of M (4 mg/kg) with dexamethasone (D) (40 mg). Vomiting lasting more than 1 hour (no protection [MP]) was the endpoint selected for the analysis. A logistic model carried out, first on the 110 subjects receiving the M+D regimen and then on the whole sample, selected sex (P = 0.0001), Eastern Cooperative Oncology Group performance status (PS) (P = 0.006), and age (P = 0.01) among the six factors considered. Since the prognostic value of these variables is mostly related to their interaction, three major risk classes were identified. The corresponding NP rates were 26.3{\%}, 42.4{\%}, and 70.8{\%} for the low-risk, intermediate-risk, and high-risk groups, respectively (P = 0.000002). Except for the lowest M level, the observed NP rates were significantly associated to the risk classes, whereas the antiemetic regimen influenced the antiemetic outcome only in the low-risk class. Regardless of the regimen employed, certain patient characteristics, such as sex, PS, and age, significantly affect cisplatin-related emesis and should be carefully considered in planning further studies.",
author = "Pollera, {C. F.} and D. Giannarelli",
year = "1989",
language = "English",
volume = "64",
pages = "1117--1122",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model

AU - Pollera, C. F.

AU - Giannarelli, D.

PY - 1989

Y1 - 1989

N2 - Data obtained from 209 patients who entered different prospective randomized antiemetic trials were analyzed to establish the prognostic value of some variables on the control of cisplatin-induced emesis. The antiemetic regimens evaluated included the following: metoclopramide (M) at 1, 2, and 4 mg/kg total dose and a combination of M (4 mg/kg) with dexamethasone (D) (40 mg). Vomiting lasting more than 1 hour (no protection [MP]) was the endpoint selected for the analysis. A logistic model carried out, first on the 110 subjects receiving the M+D regimen and then on the whole sample, selected sex (P = 0.0001), Eastern Cooperative Oncology Group performance status (PS) (P = 0.006), and age (P = 0.01) among the six factors considered. Since the prognostic value of these variables is mostly related to their interaction, three major risk classes were identified. The corresponding NP rates were 26.3%, 42.4%, and 70.8% for the low-risk, intermediate-risk, and high-risk groups, respectively (P = 0.000002). Except for the lowest M level, the observed NP rates were significantly associated to the risk classes, whereas the antiemetic regimen influenced the antiemetic outcome only in the low-risk class. Regardless of the regimen employed, certain patient characteristics, such as sex, PS, and age, significantly affect cisplatin-related emesis and should be carefully considered in planning further studies.

AB - Data obtained from 209 patients who entered different prospective randomized antiemetic trials were analyzed to establish the prognostic value of some variables on the control of cisplatin-induced emesis. The antiemetic regimens evaluated included the following: metoclopramide (M) at 1, 2, and 4 mg/kg total dose and a combination of M (4 mg/kg) with dexamethasone (D) (40 mg). Vomiting lasting more than 1 hour (no protection [MP]) was the endpoint selected for the analysis. A logistic model carried out, first on the 110 subjects receiving the M+D regimen and then on the whole sample, selected sex (P = 0.0001), Eastern Cooperative Oncology Group performance status (PS) (P = 0.006), and age (P = 0.01) among the six factors considered. Since the prognostic value of these variables is mostly related to their interaction, three major risk classes were identified. The corresponding NP rates were 26.3%, 42.4%, and 70.8% for the low-risk, intermediate-risk, and high-risk groups, respectively (P = 0.000002). Except for the lowest M level, the observed NP rates were significantly associated to the risk classes, whereas the antiemetic regimen influenced the antiemetic outcome only in the low-risk class. Regardless of the regimen employed, certain patient characteristics, such as sex, PS, and age, significantly affect cisplatin-related emesis and should be carefully considered in planning further studies.

UR - http://www.scopus.com/inward/record.url?scp=0024320125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024320125&partnerID=8YFLogxK

M3 - Article

C2 - 2667749

AN - SCOPUS:0024320125

VL - 64

SP - 1117

EP - 1122

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -